Hematologic Malignancies

Strong Responses Seen with Bortezomib-based Therapy after Relapse in Multiple Myeloma

For patients with relapsed or refractory multiple myeloma (MM), bortezomib-based therapy is effective after lenalidomide plus dexamethasone (LD), according to a Canadian study that evaluated sequencing of novel agents presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.

Low Recurrence Rate after Robot-Assisted Radical Prostatectomy
In a long-term study of men who underwent robot-assisted radical prostatectomy (RARP) nearly 87% had no recurrence of the disease after 5 years.
 
The study cohort included 1384 men who were diagnosed with moderately aggressive localized prostate cancer and underwent RARP between September 2001 and May 2005 at a tertiary center. Their average age was 60 years.
 
CRT Response Helps Predict Benefit from Adjuvant Chemotherapy in Rectal Cancer
Use of adjuvant chemotherapy may need to be rethought for patients who experience a pathologic complete response (pCR) or with ypT3-4 residual tumor after neoadjuvant chemoradiation (CRT) for rectal cancer, according to a new analysis presented at the 2011 Gastrointestinal Cancers Symposium (Abstract 361).